Vanda, AnaptysBio secure global license for GPP therapy

Vanda Pharmaceuticals and AnaptysBio have entered into an exclusive global license agreement to develop and commercialize imsidolimab, an IL-36R antagonist, for treating Generalized Pustular Psoriasis (GPP). The agreement follows successful completion of two Phase III trials, GEMINI-1 and GEMINI-2, which demonstrated the drug's safety and efficacy. Vanda will pay Anaptys an upfront fee of $10 million, with additional payments tied to regulatory milestones and a 10% royalty on net sales. GPP is a rare skin disorder that results from mutations in the IL36RN gene, leading to severe inflammation and potential systemic complications. Vanda plans to initiate technology transfer and prepare for regulatory submissions in 2025, aiming to leverage its expertise in rare diseases for further label expansions. Both companies express optimism about the potential benefits of imsidolimab in treating inflammatory conditions beyond GPP.